Our results demonstrate that LY500307 treatment causes cell cycle arrest of GBM cells in G2/M phase and increases the expression of p21 and GADD45A in GBM cells also confirms the earlier observations in other model cells. This evidence concerns the gene CDKN1A and glioblastoma.